US · ARCT · BIOTECHNOLOGY
Arcturus Therapeutics Holdings Inc. (ARCT) intrinsic value and stock valuation
$7.45as of 2026-11-21 · Mkt cap 177.93M
Data updated · price as of 2026-11-21
- P/E
- Pro
- P/B
- Pro
- P/S
- Pro
Price history
Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.
Arcturus Therapeutics Holdings Inc. DCF and intrinsic value
InvestorsCraft values ARCT with the Chepakovich two-stage DCF model — currently rated strongly undervalued. How the model works · Run your own DCF prefilled from ARCT’s statements →
Arcturus Therapeutics Holdings Inc. Graham Number
The Graham Number is not defined for negative earnings or book value. Guide · Calculator →
How the business is doing
Fiscal 2011–2025, USD
Is it expensive?
Each multiple against its own 15-year range, or against peers where no history is available
Peers
Same-industry companies, ranked by market cap
- Achieve Life Sciences, Inc. (ACHV) $6.78
- Zura Bio Limited (ZURA) $0.93
- Atea Pharmaceuticals, Inc. (AVIR) $3.96
- Vanda Pharmaceuticals Inc. (VNDA) $3.45
- Foghorn Therapeutics Inc. (FHTX) $1.72
- Sagimet Biosciences Inc. (SGMT) $9.08
- Entrada Therapeutics, Inc. (TRDA) $4.35
- Voyager Therapeutics, Inc. (VYGR) $1.53
Peer comparison
The peer comparison table is shown only to users with a Pro subscription.
Financials
Statements by fiscal year
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $67.2M | $138.4M | $157.8M | $205.8M | $12.4M |
| Operating income | -$-74.95M | -$-95.67M | -$-78.2M | $12.2M | -$-202.85M |
| Net income | -$-65.78M | -$-80.94M | -$-29.73M | $9.35M | -$-203.67M |
| EPSd | -$-2.4M | -$-3M | -$-1.12M | $345.1K | -$-7.74M |
| Operating cash flow | -$-74.27M | -$-59.75M | -$-18.1M | $32M | -$-135.04M |
| Capital expenditure | -$-230K | -$-650K | -$-2.9M | -$-7.73M | -$-3.41M |
| Free cash flow | -$-74.27M | -$-60.4M | -$-21M | $24.3M | -$-138.45M |
| Total assets | $271.2M | $344.1M | $429.4M | $450.4M | $392.8M |
| Total debt | $25M | $28.6M | $30.2M | $94.8M | $69.2M |
| Net debt | -$-205.91M | -$-208.48M | -$-261.79M | -$-297.13M | -$-301.35M |
| Total equity | $214M | $241M | $278.5M | $270.3M | $228.2M |
| Cash and short-term investments | $230.9M | $237M | $292M | $391.9M | $370.5M |
Income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $67.2M | $138.4M | $157.8M | $205.8M | $12.4M |
| Cost of revenue | $3.02M | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross profit | $64.2M | $138.4M | $157.8M | $205.8M | $12.4M |
| Research and development expenses | $112.2M | $195.2M | $192.1M | $147.8M | $173.8M |
| Selling, general and administrative expenses | $46.1M | $52.8M | $52.9M | $46.1M | $41.5M |
| Other expenses | -$-19.14M | -$-13.92M | -$-9.05M | -$-240K | $0.00 |
| Operating expenses | $139.2M | $234.1M | $236M | $193.6M | $215.2M |
| Cost and expenses | $142.2M | $234.1M | $236M | $193.6M | $215.2M |
| Interest income | $10.1M | $15.2M | $17.4M | $2.58M | $750K |
| Interest expense | $0.00 | $0.00 | $770K | $3M | $2.67M |
| Depreciation and amortization | $3.02M | $3.54M | $2.96M | $1.53M | $1.19M |
| Ebitda | -$-62.76M | -$-77.4M | -$-24.16M | $15.2M | -$-199.81M |
| Operating income | -$-74.95M | -$-95.67M | -$-78.2M | $12.2M | -$-202.85M |
| Total other income/expenses, net | $9.17M | $14.7M | $50.3M | -$-1.53M | -$-820K |
| Income before tax | -$-65.78M | -$-80.94M | -$-27.89M | $10.6M | -$-203.67M |
| Income tax expense | $0.00 | -$0.00 | $1.83M | $1.29M | $0.00 |
| Net income | -$-65.78M | -$-80.94M | -$-29.73M | $9.35M | -$-203.67M |
| Weighted average shares outstanding | $27.4M | $27M | $26.6M | $26.5M | $26.3M |
| Weighted average diluted shares outstanding | $27.4M | $27M | $26.6M | $27.1M | $26.3M |
Balance sheet
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Cash and short-term investments | $230.9M | $237M | $292M | $391.9M | $370.5M |
| Net receivables | $5.56M | $3.97M | $32.1M | $2.76M | $3.37M |
| Inventory | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total current assets | $241.5M | $306M | $386.6M | $403.3M | $379M |
| Property, plant and equipment, net | $27.8M | $36.2M | $40.9M | $45M | $11.3M |
| Goodwill and intangible assets | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Long-term investments | $1.89M | $0.00 | $1.89M | $0.00 | $520K |
| Total non-current assets | $29.7M | $38.1M | $42.8M | $47.1M | $13.9M |
| Total assets | $271.2M | $344.1M | $429.4M | $450.4M | $392.8M |
| Accounts payable | $4.24M | $7.19M | $5.28M | $7.45M | $10.1M |
| Short-term debt | $4.21M | $3.55M | $4.31M | $64.5M | $24M |
| Deferred revenue | $8.25M | $21.9M | $47.3M | $36.1M | $43.5M |
| Total current liabilities | $36.4M | $65.5M | $82M | $127M | $99.5M |
| Long-term debt | $20.8M | $25M | $25.9M | $30.2M | $45.1M |
| Deferred revenue, non-current | $0.00 | $12.6M | $42.5M | $20.1M | $0.00 |
| Total non-current liabilities | $20.8M | $37.6M | $68.9M | $53.1M | $65.1M |
| Capital lease obligations | $25M | $28.6M | $30.2M | $34.1M | $6.04M |
| Total liabilities | $57.2M | $103.1M | $150.9M | $180.1M | $164.6M |
| Common stock | $30K | $30K | $30K | $30K | $30K |
| Retained earnings | -$-514.59M | -$-448.81M | -$-367.87M | -$-338.14M | -$-347.49M |
| Accumulated other comprehensive income (loss) | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total equity | $214M | $241M | $278.5M | $270.3M | $228.2M |
| Total investments | $1.89M | $0.00 | $1.89M | $0.00 | $520K |
| Total debt | $25M | $28.6M | $30.2M | $94.8M | $69.2M |
| Net debt | -$-205.91M | -$-208.48M | -$-261.79M | -$-297.13M | -$-301.35M |
Cash flow statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Net income | -$-65.78M | -$-80.94M | -$-29.73M | $9.35M | -$-203.67M |
| Depreciation and amortization | $3.02M | $3.54M | $2.96M | $1.53M | $1.19M |
| Stock-based compensation | $25.4M | $38M | $34.7M | $30.6M | $28.9M |
| Change in working capital | -$-39.2M | -$-20.81M | $7.38M | -$-12.56M | $32.6M |
| Accounts receivable | -$-1.59M | $28.1M | -$-29.3M | $600K | -$-1.24M |
| Inventory | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Accounts payable | -$-2.96M | $1.92M | -$-2.24M | -$-3.11M | -$-770K |
| Net cash provided by operating activities | -$-74.27M | -$-59.75M | -$-18.1M | $32M | -$-135.04M |
| Investments in property, plant and equipment | -$-230K | -$-650K | -$-2.9M | -$-7.73M | -$-3.41M |
| Acquisitions, net | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net cash used for investing activities | -$-230K | -$-650K | -$-2.9M | -$-7.73M | -$-3.41M |
| Common stock issued | $13.4M | $680K | $610K | $410K | $520K |
| Common stock repurchased | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Dividends paid | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net cash used for financing activities | $13.4M | $5.42M | -$-24.09M | -$-2.86M | $48M |
| Net change in cash | -$-61.12M | -$-54.98M | -$-45.09M | $21.4M | -$-90.43M |
| Cash at end of period | $232.8M | $293.9M | $348.9M | $394M | $372.6M |
| Operating cash flow | -$-74.27M | -$-59.75M | -$-18.1M | $32M | -$-135.04M |
| Capital expenditure | -$-230K | -$-650K | -$-2.9M | -$-7.73M | -$-3.41M |
| Free cash flow | -$-74.27M | -$-60.4M | -$-21M | $24.3M | -$-138.45M |
Line items
Line items
Line items
About Arcturus Therapeutics Holdings Inc.
Arcturus Therapeutics Holdings Inc. is a biotechnology company focused on RNA-based medicines, developing a pipeline of vaccines for infectious diseases alongside treatments for rare liver and respiratory conditions across the United States. Its notable development programs encompass LUNAR-OTC, designed for ornithine transcarbamylase (OTC) deficiency, and LUNAR-CF, targeting cystic fibrosis lung disease caused by specific CFTR gene mutations. The company also advances vaccine initiatives such as LUNAR-COV19 and LUNAR-FLU. Arcturus has cultivated a range of strategic collaborations, including partnerships with Vinbiocare Biotechnology Joint Stock Company for manufacturing COVID-19 vaccines; Janssen Pharmaceuticals, Inc., to create nucleic acid-based therapies for hepatitis B virus; Ultragenyx Pharmaceutical, Inc., for developing mRNA therapeutics aimed at rare disease targets; CureVac AG, to progress mRNA therapeutic and vaccine candidates across various indications; the Singapore Economic Development Board and Duke-NUS Medical School, specifically for the LUNAR-COV19 vaccine; and Millennium Pharmaceuticals, Inc., focused on discovering siRNA medicines for non-alcoholic steatohepatitis (NASH). Founded in 2013, Arcturus Therapeutics maintains its corporate headquarters in San Diego, California.
- CEO
- Joseph E. Payne
- Employees
- 111
- Beta
- 2.36
Explore
Frequently asked questions
What is the intrinsic value of Arcturus Therapeutics Holdings Inc. (ARCT)?
Arcturus Therapeutics Holdings Inc. (ARCT) is currently strongly undervalued based on the InvestorsCraft IC model — IC value is more than 50% above the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.
Is ARCT undervalued?
ARCT trades at a price of $7.45 (Nov 21, 2026): strongly undervalued — IC value is more than 50% above the price.
How is the intrinsic value calculated?
InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.
How often is this page updated?
Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.